Company
LON:C4XD
C4X Discovery Holdings PLC is a pioneering drug discovery company combining scientific expertise with cutting-edge drug discovery technologies to efficiently deliver world leading medicines. The company has a highly valuable and differentiated approach to drug discovery through its enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. C4X Discovery's commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage drug discovery programmes ready for out-licensing to partners and it has two commercially partnered programmes with one candidate in clinical development.
96 stories · page 2 of 5
Archive
20 October 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**Ithaca Energy, a UK independen
It is working with HitGen Inc, a Shanghai-listed group
Larger drugs companies are looking to snap up new technologies or promising treatments before their rivals and are willing to pay well for the privilege
The cornerstone investor will be the Polar Capital Biotechnology Fund
It said it hopes to have the deal for its NRF2 activator programme for inflammatory diseases signed sometime in the second half of this year
The drug developer will also get royalty payments from future sales of the oral interleukin 17A inhibitor under a pre-agreed licensing deal
The update was provided alongside the company's prelims
Dr Catherine Jane Tralau-Stewart's forte is forging commercial relationships between drug companies and academia
“Following the €414mln agreement with Sanofi for our IL-17A oral Inhibitor programme, C4XD is focused on driving forward its portfolio towards future out-licensing opportunities, including NRF-2 where there is significant partnering interes
Dr Mario Polywka will replace Harry Finch in January
“Clive is a veteran of the UK biotechnology industry with more than 30 years of experience, with a strong track record as a serially successful entrepreneur and an experienced pharmaceutical R&D executive," said C4X Discovery chair Eva-Lott
The search for a new chief science officer is already under way, the company said
The drug discovery firm said it has enough funding for the foreseeable future
The drug discovery engine is eyeing future partnerships after securing deals with Sanofi and Indivior
New director Simon Harford will be invaluable as the company continues to grow and expedite major out-licensing deals, said chair Eva-Lotta Allan.
Here we take a detailed look at drug discovery company C4X
Archive
A look at some of the major headlines from the Proactive newswire
The French drugs giant will help develop an oral IL-17 inhibitor to treat inflammatory diseases - tapping into a multi-billion-dollar market
“With robust finances now in place, we are strongly positioned to generate commercially attractive data packages for future partners.”
The UK is the first country to start a mass coronavirus vaccination programme
